0001179110-12-015057.txt : 20121010 0001179110-12-015057.hdr.sgml : 20121010 20121010172204 ACCESSION NUMBER: 0001179110-12-015057 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20121008 FILED AS OF DATE: 20121010 DATE AS OF CHANGE: 20121010 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SHEMA SUZANNE M CENTRAL INDEX KEY: 0001225509 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28298 FILM NUMBER: 121138370 MAIL ADDRESS: STREET 1: C/O ZYMOGENETICS, INC. STREET 2: 1201 EASTLAKE AVENUE CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ONYX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001012140 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943154463 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-266-0000 MAIL ADDRESS: STREET 1: 249 E. GRAND AVE. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 edgar.xml FORM 4 - X0306 4 2012-10-08 0 0001012140 ONYX PHARMACEUTICALS INC ONXX 0001225509 SHEMA SUZANNE M C/O ONYX PHARMACEUTICALS, INC. 249 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 EVP, GC and Corp. Secretary Common Stock 2012-10-08 4 M 0 656 30.28 A 36803 D Common Stock 2012-10-08 4 M 0 1344 32.07 A 38147 D Common Stock 2012-10-08 4 S 0 2000 91.01 D 36147 D Stock Option (Right to Buy) 30.28 2012-10-08 4 M 0 656 0.00 D 2020-03-31 Common Stock 656 11813 D Stock Option (Right to Buy) 32.07 2012-10-08 4 M 0 1344 0.00 D 2019-08-31 Common Stock 1344 26220 D Shares sold pursuant to a 10b5-1 plan. 12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months. 25% of the shares subject to the option become exercisable one year following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 36 months for a total vesting schedule of 48 months. /s/ Warren DeSouza, Attorney-in-fact 2012-10-08